FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3040981454> ?p ?o ?g. }

• W3040981454 abstract "BACKGROUND: Ovarian cancer is the most lethal gynecologic malignancy. While women with BRCA deficient tumors show sensitivity to PARP inhibitors (PARPi), new treatment options are urgently needed for patients with PARPi-resistant tumors. An emerging strategy to improve PARPi response is combination therapy with epigenetic drugs. A recently recognized epigenetic drug target in ovarian cancer is the bromodomain and extraterminal (BET) family of proteins. BET proteins such as BRD4 promote oncogenic transcription of genes promoting cell growth, survival and DNA repair. One example is the well-established link between inflammation and cancer, nuclear factor-kappaB (NF-κB). In syngeneic mouse ovarian cancer models, M2-like pro-tumor macrophages are a prominent component of the ovarian cancer tumor microenvironment (TME). NF-κB inhibition can reduce the M2 macrophage population; however, more sustained treatment with a systemic NF-κB inhibitor leads to more ascites and reduced survival time. Thus, BET inhibitors (BETi) have the potential to induce transcriptional reprogramming in tumors and macrophages that may be beneficial or harmful depending on context. OBJECTIVE: To determine the cellular and molecular effects of combining BETi and PARPi in mouse ovarian cancer cells and peritoneal macrophages. METHODS: Cultured ID8 mouse ovarian cancer cells, PMJ2-PC mouse peritoneal macrophages and immortalized bone marrow-derived macrophages were treated with vehicle, the PARPi olaparib, the BETi JQ1 or the JQ1/olaparib combination for 24-72h. Sulforhodamine B (SRB) assays assessed cell growth in vitro. C57BL/6 mice injected intra-peritoneally (IP) with ID8 cells were treated with JQ1 (30 days, 50mg/kg by IP injection) with volume of ascites fluid, weight of harvested tumor, and number of tumor implants assessed. Markers of apoptosis (cleaved PARP or cleaved caspase-3), and DNA damage (pH2AX) were measured by immunohistochemistry or western blot. NF-κB activity was measured by luciferase assays of a NF-κB reporter plasmid. Expression of M1 (CCL3) and M2 (CD206, arginase-1) macrophage markers was measured by quantitative real-time RT-PCR (QPCR). RESULTS: In culture, JQ1 treatment sensitized ID8 ovarian cancer cells to olaparib-induced growth inhibition, DNA damage and apoptosis. However, despite modest stimulatory effects on DNA damage and apoptosis of long-term JQ1 treatment in ID8 tumors in vivo, JQ1 unexpectedly increased ascites formation without reducing overall tumor burden. In macrophages, there were also contrasting effects between JQ1 treatment in vitro and in vivo. JQ1 alone or combined with olaparib reduced NF-κB activity in cultured macrophage cell lines, and increased expression of CCL3, and reduced CD206 and arginase-1 expression. In contrast, increased ascites due to JQ1 treatment in vivo was accompanied by a pronounced M2 macrophage shift. CONCLUSIONS: Sustained inhibition of NF-κB activity in macrophages and potentially other cells in the ovarian TME could have overall deleterious effects on tumor progression. Our results strongly suggest that the therapeutic effects of BETi in ovarian cancer, and any therapeutic agent with the potential to alter cell function in the tumor microenvironment, need to be more thoroughly tested in the context of functional immune system before being translated to patients. This is particularly relevant since BETi are currently being tested in human patients in early clinical trials. Citation Format: Andrew J. Wilson, Alyssa Hoover, Whitney Harris, Esther Liu, Dineo Khabele, Fiona E. Yull. BROMODOMAIN INHIBITION IN OVARIAN CANCER AND THE TUMOR MICROENVIRONMENT [abstract]. In: Proceedings of the 12th Biennial Ovarian Cancer Research Symposium; Sep 13-15, 2018; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2019;25(22 Suppl):Abstract nr TMIM-085." @default.
• W3040981454 created "2020-07-16" @default.
• W3040981454 creator A5003848046 @default.
• W3040981454 creator A5014078497 @default.
• W3040981454 creator A5014481026 @default.
• W3040981454 creator A5038806823 @default.
• W3040981454 creator A5050957879 @default.
• W3040981454 creator A5059352804 @default.
• W3040981454 date "2019-11-15" @default.
• W3040981454 modified "2023-09-27" @default.
• W3040981454 title "Abstract TMIM-085: BROMODOMAIN INHIBITION IN OVARIAN CANCER AND THE TUMOR MICROENVIRONMENT" @default.
• W3040981454 doi "https://doi.org/10.1158/1557-3265.ovcasymp18-tmim-085" @default.
• W3040981454 hasPublicationYear "2019" @default.
• W3040981454 type Work @default.
• W3040981454 sameAs 3040981454 @default.
• W3040981454 citedByCount "0" @default.
• W3040981454 crossrefType "proceedings-article" @default.
• W3040981454 hasAuthorship W3040981454A5003848046 @default.
• W3040981454 hasAuthorship W3040981454A5014078497 @default.
• W3040981454 hasAuthorship W3040981454A5014481026 @default.
• W3040981454 hasAuthorship W3040981454A5038806823 @default.
• W3040981454 hasAuthorship W3040981454A5050957879 @default.
• W3040981454 hasAuthorship W3040981454A5059352804 @default.
• W3040981454 hasConcept C104317684 @default.
• W3040981454 hasConcept C121608353 @default.
• W3040981454 hasConcept C126322002 @default.
• W3040981454 hasConcept C134935766 @default.
• W3040981454 hasConcept C182979987 @default.
• W3040981454 hasConcept C203014093 @default.
• W3040981454 hasConcept C2776107976 @default.
• W3040981454 hasConcept C2778502085 @default.
• W3040981454 hasConcept C2779138821 @default.
• W3040981454 hasConcept C2779962180 @default.
• W3040981454 hasConcept C2780427987 @default.
• W3040981454 hasConcept C2908647359 @default.
• W3040981454 hasConcept C3020616263 @default.
• W3040981454 hasConcept C41091548 @default.
• W3040981454 hasConcept C502942594 @default.
• W3040981454 hasConcept C55493867 @default.
• W3040981454 hasConcept C71924100 @default.
• W3040981454 hasConcept C74401373 @default.
• W3040981454 hasConcept C82381507 @default.
• W3040981454 hasConcept C86803240 @default.
• W3040981454 hasConcept C96232424 @default.
• W3040981454 hasConcept C99454951 @default.
• W3040981454 hasConceptScore W3040981454C104317684 @default.
• W3040981454 hasConceptScore W3040981454C121608353 @default.
• W3040981454 hasConceptScore W3040981454C126322002 @default.
• W3040981454 hasConceptScore W3040981454C134935766 @default.
• W3040981454 hasConceptScore W3040981454C182979987 @default.
• W3040981454 hasConceptScore W3040981454C203014093 @default.
• W3040981454 hasConceptScore W3040981454C2776107976 @default.
• W3040981454 hasConceptScore W3040981454C2778502085 @default.
• W3040981454 hasConceptScore W3040981454C2779138821 @default.
• W3040981454 hasConceptScore W3040981454C2779962180 @default.
• W3040981454 hasConceptScore W3040981454C2780427987 @default.
• W3040981454 hasConceptScore W3040981454C2908647359 @default.
• W3040981454 hasConceptScore W3040981454C3020616263 @default.
• W3040981454 hasConceptScore W3040981454C41091548 @default.
• W3040981454 hasConceptScore W3040981454C502942594 @default.
• W3040981454 hasConceptScore W3040981454C55493867 @default.
• W3040981454 hasConceptScore W3040981454C71924100 @default.
• W3040981454 hasConceptScore W3040981454C74401373 @default.
• W3040981454 hasConceptScore W3040981454C82381507 @default.
• W3040981454 hasConceptScore W3040981454C86803240 @default.
• W3040981454 hasConceptScore W3040981454C96232424 @default.
• W3040981454 hasConceptScore W3040981454C99454951 @default.
• W3040981454 hasLocation W30409814541 @default.
• W3040981454 hasOpenAccess W3040981454 @default.
• W3040981454 hasPrimaryLocation W30409814541 @default.
• W3040981454 hasRelatedWork W10013529 @default.
• W3040981454 hasRelatedWork W12726368 @default.
• W3040981454 hasRelatedWork W13281499 @default.
• W3040981454 hasRelatedWork W2880624 @default.
• W3040981454 hasRelatedWork W2993405 @default.
• W3040981454 hasRelatedWork W3651239 @default.
• W3040981454 hasRelatedWork W7190444 @default.
• W3040981454 hasRelatedWork W8514342 @default.
• W3040981454 hasRelatedWork W4714080 @default.
• W3040981454 hasRelatedWork W6893594 @default.
• W3040981454 isParatext "false" @default.
• W3040981454 isRetracted "false" @default.
• W3040981454 magId "3040981454" @default.
• W3040981454 workType "article" @default.